Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
With Its GLP-1 Drugs No Longer in a Shortage, Is Now the Time to Buy Eli Lilly Stock?
While artificial intelligence (AI) has been one of the hottest investing trends, GLP-1 weight loss drugs are a close second. Demand for Eli Lilly's Mounjaro and Zepbound remains robust, and sell-side analysts tracking script data shows strong growth for both of these drugs.
Compounders sue FDA for removing Eli Lilly's tirzepatide from shortage list
With an estimated 2 million people in the United States taking copycat vers | A compounding industry group has sued the FDA, claiming its action to remove Eli Lilly’s Mounjaro and Zepbound from its drug shortage list is a “reckless and arbitrary decision—lacking any semblance of lawful process.
Eli Lilly Stock Soars In 2024 On Weight Loss Drug Success, Now The Company Wants Medical Records Of Copycat Treatments
To fight off compounding pharmacies, Eli Lilly wants access to medical records of patients who used copycat products.
What end of Eli Lilly's weight-loss drug shortage means for the competition
The FDA confirmed Thursday that Eli Lilly has increased production of its blockbuster weight-loss drug Zepbound and type 2 diabetes drug Mounjaro, implying the company can now supply enough doses to meet current demand.
End of Zepbound Shortage Threatens $1 Billion Knockoff Weight-Loss Shot Industry
Americans who turned to telehealth companies and compounding pharmacies for cheap versions of Eli Lilly & Co.’s weight-loss drugs are scrambling to figure out if they’ll still have access after US regulators signaled an end to their unfettered use.
Hims & Hers Health stock tanks after FDA says competitor Eli Lilly’s weight-loss drug shortage is over
The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 medications. Shares of Hims & Hers Health fell almost 10% today following an announcement from the U.
Eli Lilly’s Weight-Loss, Diabetes Drug Shortages Are Over, FDA Says
The removal of Zepbound and Mounjaro from the regulator’s shortage list could lead to restrictions on pharmacies making custom-made versions.
The FDA issued a warning about compounding pharmacies on weight-loss drugs
A surge of alternatives to newly popular weight-loss drugs is facing its biggest test yet after the FDA warned companies against skirting regulatory standards to put them on the market now that shortages are waning.
Hims & Hers Health Stock Falls as FDA Drops Eli Lilly Weight-Loss Drugs From Shortage List
Key Takeaways Hims & Hers Health shares tumbled Thursday after the Food and Drug Administration (FDA) said Eli Lilly's popular weight-loss drugs are no longer on its list of drugs in short supply. The FDA allows companies to produce compounded copycat drugs when the originals are hard to obtain,
Zepbound is no longer in shortage. That could hurt off-brand weight loss drug sellers
The shortage of Eli Lilly’s (LLY) blockbuster diabetes and weight loss drugs is officially over, according to the U.S. Food and Drug Administration (FDA).
1d
on MSN
Billion-Dollar News for Eli Lilly Stock Investors
Eli Lilly shares have soared thanks to excitement about the company's position in the weight loss drug market.
5d
on MSN
Eli Lilly plans $4.5 billion facility in LEAP District, bringing investment to $13 billion
The $4.5 billion investment will create the Lilly Medicine Foundry, a center that will combine research and manufacturing ...
6d
on MSN
Eli Lilly to build $4.5 billion research and manufacturing center to propel drug pipeline
Lilly has 11 obesity drugs in its pipeline and wants to develop more treatments for Alzheimer's disease, ALS and other brain ...
bovnews
16h
Eli Lilly And Co (LLY) Posted 18.86% Profit Margin Last Year—Can It Hold Up?
On Monday, Eli Lilly And Co (LLY) stock saw a modest uptick, ending the day at $898.4 which represents a slight increase of $11.24 or 1.27% from the prior close of $887.16. The stock opened at $890.51 ...
19h
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Abivax SA Sponsored ADR (ABVX) and Aquestive Therapeutics (AQST)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Eli Lilly & Co (LLY – Research ...
6d
on MSN
Eli Lilly to build $4.5 billion Indiana facility for advanced drug manufacturing
Eli Lilly said Wednesday it will invest $4.5 billion to build an advanced pharmaceutical drug manufacturing and development ...
6d
on MSN
Drugmaker Lilly slates another $4.5B for manufacturing and drug development improvements
Lilly will add the center to a site in Lebanon, Indiana, where it is already spending about $9 billion to improve ...
4d
Evaluating Eli Lilly Against Peers In Pharmaceuticals Industry
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include ...
1d
on MSN
Eli Lilly and Company (LLY): Hedge Funds Are Bullish On This Momentum Stock Now
We recently compiled a list of the 8 Best Momentum Stocks To Invest In Right Now. In this article, we are going to take a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Zepbound
Mounjaro
Indiana
Feedback